Astrazeneca Ord Shs AZNCF

Healthcare

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.

OTCPK:AZNCF - Post by User

Astrazeneca Ord Shs

<< Previous

Bullboard Posts

Post by whytestockson Feb 19, 2024 2:30am

363 Views

Post# 35887256

Datopotamab Deruxtecan Biologics License Application Accepte

Just In: $AZN Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung CancerApplication based on results from the TROPION-Lung01 phase 3 trial If approved, Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan may be the first TROP2 directed antibody drug conjugate for patients with lung cancer Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (L...AZN - Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

<< Previous

Bullboard Posts

Cyberattack will leave lasting reputational damage to London Drugs